• Donor Login
  • Contact Us
  • JDRF
JDRF T1D Fund
  • About
  • Investment Strategy
  • Portfolio
  • Our People
  • Venture Philanthropy
  • News
  • Donor Login
  • Get in touch

News and Press

Abata Announces Formation of Advisory Board Comprised of Leading Industry Experts in Treg Biology, Cell Therapy and Corporate Development

April 06, 2022 | Boston, MA

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

April 04, 2022 | WATERTOWN, Mass.

Jaguar Gene Therapy Announces Samsung and JDRF T1D Fund as New Investors

March 29, 2022 | LAKE FOREST, Ill.

Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial

March 15, 2022 | MONTREAL (CANADA)

Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases

February 22, 2022 | Greater Philadelphia, Pa.

About the JDRF T1D Fund

Our aim is to create a new investment market aimed at delivering solutions to those living with or at risk of developing T1D. Launched in December 2016, the T1D Fund is a combination of venture capital and philanthropy focused solely on T1D. It’s the first scale, mission-driven venture philanthropy fund focused on equity investments in companies developing life-changing T1D products. The portfolio consists of therapeutics, devices, vaccines, and diagnostics. We already have made several investments and the list will only continue to grow.


  • About
  • Investment
    Strategy
  • Portfolio
  • Our People
  • Venture
    Philanthropy
  • News
Contact Us

For more information email us at t1dfund@jdrf.org

JDRF T1D Fund

© Copyright 2018. All Rights Reserved